<DOC>
	<DOC>NCT00091832</DOC>
	<brief_summary>This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.</brief_summary>
	<brief_title>Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Histologically or cytologically confirmed breast adenocarcinoma At least one bone metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Cancer</keyword>
</DOC>